T think there are important decisions that the Immutep has to made in 1H/2023.
Outlicensing the expected P3 in NSLC to Merck in combination with keytrude or doing the p3 by themselves? Therefore they would have to initiate in huge Capital increase at i guess at about 100 Million USD.
I would prefer the outlicensing deal because commercial value in USD would be shown to the market. Wat are your expectations?
T think there are important decisions that the Immutep has to...
-
- There are more pages in this discussion • 1,609 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |